January 4, 2018 / 2:49 PM / 5 months ago

BRIEF-Adverum Biotechnologies Provides 2018 Outlook

Jan 4 (Reuters) - Adverum Biotechnologies Inc:

* ADVERUM BIOTECHNOLOGIES PROVIDES 2018 OUTLOOK

* ADVERUM BIOTECHNOLOGIES INC - ADVERUM’S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $186.6 MILLION AS OF SEPTEMBER 30, 2017.

* ADVERUM BIOTECHNOLOGIES INC - CURRENT CASH POSITION IS EXPECTED TO FUND THREE LEAD GENE THERAPY PROGRAMS THROUGH END OF 2019

* ADVERUM - PLAN TO SUBMIT 2 INVESTIGATIONAL NDA WITH FDA IN H2 2018, FOR ADVM-022 IN WET AMD, ADVM-053 IN HEREDITARY ANGIOEDEMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below